Psilocybin and other psychedelics are forcing their way out of prohibition as potentially viable treatments for not only depression and anxiety but also Alzheimer’s and other neurodegenerative diseases plaguing millions in North America alone. In the end, psilocybin solutions address a $300 billion dollar psychotherapy and wellness global market.

Shroom Stocks’ own Ethan Reyes spoke with Nikita Alexandrov, CTO of ThinkMyco, to get a good look at the company, the sector and what lies ahead for investors.

Listen in!

Written By:

Ethan Reyes

More By This Author
Tags:
Biotech
Featured Content
Psychedelics
Reyes
Series
anxiety
depression
mental illness
mycology
Psilocybin
psychedelics
PTSD
ThinkMyco
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x